Emicizumab biosimilar (Prestige BioPharma)

艾美赛珠单抗生物类似药（Prestige BioPharma）

Report date: 2024/10/10 10:04:53

First In Class

Base Information

Drug NameEmicizumab biosimilar (Prestige BioPharma)

Drug Alias NameIDC2301IDC-2301

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionAnti-Factor IXaAnti-Factor XBlood coagulation pathway activation

TargetsCoagulation factor XCoagulation factor IX

Therapy Area/IndicationsHematologic Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPrestige BioPharma Ltd

China Registration ClassN/A

Develop Information

Active CompaniesPrestige BioPharma Ltd

Inactive CompaniesN/A

Active IndicationsHematologic Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A